AKT1 and neoplasm: ARID1A loss is associated with enhanced activation of the PI3K/AKT pathway in vitro [85,86], as well as activation of mTOR signalling and increased expression of SOX9, a gastrointestinal stem cell marker, in tissue microarrays, cell lines, patient xenograft tumours, and mouse models [84].